Company
Headquarters: Lhasa, China
Employees: 500
CN¥4.45 Billion
CNY as of Jan. 1, 2024
US$626.2 Million
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company's products include parenteral nutrition vitamins, electrolyte supplements, intravenous iron supplements, antibiotics, and medicine for digestive system and liver diseases. It also offers injection multivitamins, potassium magnesium aspartate for injection, iron sucrose injection, potassium aspartate injection, etc. The company was formerly known as Weixinkang Medicine Youxian Gongsi and changed its name to Tibet Weixinkang Medicine Co., Ltd. in 2015. Tibet Weixinkang Medicine Co., Ltd. was founded in 2006 and is based in Lhasa, China.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Tibet Weixinkang Medicine Co. Ltd has the following listings and related stock indices.
Stock: SSE: 603676 wb_incandescent